Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Chris Morehouse"'
Autor:
Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, Patricia LoRusso, Amy Weise, Joseph Eder, Brendan Curti, Michael Oberst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods MEDI0680 wa
Externí odkaz:
https://doaj.org/article/cf9d82e0ebcd4aaeac76ef9a975cf4f7
Autor:
Liyan Jiang, Jiaqi Huang, Brandon W Higgs, Zhibin Hu, Zhan Xiao, Xin Yao, Sarah Conley, Haihong Zhong, Zheng Liu, Philip Brohawn, Dong Shen, Song Wu, Xiaoxiao Ge, Yue Jiang, Yizhuo Zhao, Yuqing Lou, Chris Morehouse, Wei Zhu, Yinong Sebastian, Meggan Czapiga, Vaheh Oganesyan, Haihua Fu, Yanjie Niu, Wei Zhang, Katie Streicher, David Tice, Heng Zhao, Meng Zhu, Lin Xu, Ronald Herbst, Xinying Su, Yi Gu, Shyoung Li, Lihua Huang, Jianren Gu, Baohui Han, Bahija Jallal, Hongbing Shen, Yihong Yao
Publikováno v:
PLoS Genetics, Vol 12, Iss 4, p e1005895 (2016)
Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in SCLC, however, much still remains unknown, particularly in the
Externí odkaz:
https://doaj.org/article/5a94d0c0e61d478c84e2d5a2d8db5b34
Autor:
Li Peng, Michael D Oberst, Jiaqi Huang, Philip Brohawn, Chris Morehouse, Kristen Lekstrom, Patrick A Baeuerle, Herren Wu, Yihong Yao, Steven R Coats, William Dall'Acqua, Melissa Damschroder, Scott A Hammond
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e36412 (2012)
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in development for the treatment of patients with cancers expressing carcinoembryonic antigen (CEA). MEDI-565 binds CEA on cancer cells and CD3 on T cells to induce T-cel
Externí odkaz:
https://doaj.org/article/da294e9bbf4741419797c4c6311d44f6
Autor:
Jiaqi Huang, Chris Morehouse, Katie Streicher, Brandon W Higgs, Jin Gao, Meggan Czapiga, Anmarie Boutrin, Wei Zhu, Philip Brohawn, Yong Chang, Jaye Viner, Theresa LaVallee, Laura Richman, Bahija Jallal, Yihong Yao
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e26177 (2011)
PURPOSE: Insulin-like growth factor (IGF) signaling through human insulin receptor isoform A (IR-A) contributes to tumorigenesis and intrinsic resistance to anti-IGF1R therapy. In the present study, we (a) developed quantitative TaqMan real time-PCR-
Externí odkaz:
https://doaj.org/article/bbcf5b03c12049078f8d5f6ebd89e2ef
Autor:
Yihong Yao, Laura Richman, Chris Morehouse, Melissa de los Reyes, Brandon W. Higgs, Anmarie Boutrin, Barbara White, Anthony Coyle, James Krueger, Peter A. Kiener, Bahija Jallal
Publikováno v:
PLoS ONE, Vol 4, Iss 3 (2009)
Externí odkaz:
https://doaj.org/article/4a4d1a9b85d548c28cbfcd4104728447
Autor:
Yihong Yao, Laura Richman, Chris Morehouse, Melissa de los Reyes, Brandon W Higgs, Anmarie Boutrin, Barbara White, Anthony Coyle, James Krueger, Peter A Kiener, Bahija Jallal
Publikováno v:
PLoS ONE, Vol 3, Iss 7, p e2737 (2008)
BACKGROUND: Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. To better understand the pathogenesis of this disease and identify potential mediator
Externí odkaz:
https://doaj.org/article/6656647cca6841ab9c2874f8e6592ec6
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Supplementary Figures S1-S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447a2faa43430fbac4574cf80676b109
https://doi.org/10.1158/1078-0432.22477526
https://doi.org/10.1158/1078-0432.22477526
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Purpose:While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b977133483ab014e3abfe875a2074603
https://doi.org/10.1158/1078-0432.c.6529685
https://doi.org/10.1158/1078-0432.c.6529685
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e329b32ceccaccb01d825f32846ab6
https://doi.org/10.1158/1078-0432.22477523
https://doi.org/10.1158/1078-0432.22477523
Autor:
Kristen Arnold, Chris Morehouse, Eleanor Clancy-Thompson, Katharina Deschler, Susannah Hewitt, Russell Karp, Ameya Apte, Chris Bagnall, Faith Musenge, Darren Potz, David A. Leinster, Kathy Mulgrew, Ankita Mishra, Gordon Moody, Maja Sedic, Joshua Frederick, John Zielinski, Fabien Garcon, Sushma Gurumurthy, Nadia Luheshi, Michal Sulikowski, Steve Novick, Han Si, Philip Martin, Grace Adjei, James Moynihan, Jean-Martin Lapointe, Amanda Watkins, Shannon Burke, Ronald Herbst, Dyane Bailey, Robert W. Wilkinson
Publikováno v:
Clinical Cancer Research. 26:6284-6298
Purpose: While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5aa76c833838d68d2852862e2fa941
https://doi.org/10.1158/1078-0432.ccr-20-0472
https://doi.org/10.1158/1078-0432.ccr-20-0472